Search results
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
Zacks via Yahoo Finance· 2 weeks agoNovavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with
Guru Focus· 2 weeks agoThe company, a prominent player in the biotechnology sector focusing on the development of vaccines, reported a net loss of $147.55 million with a loss per share of $1.05.
3 Things You Need to Know If You Buy Novavax Today | The Motley Fool
The Motley Fool· 2 days agoNovavax (NVAX 5.30%) stock has both soared and plummeted at times in recent years. Investors...
Earnings call: Novavax strikes multibillion-dollar deal with Sanofi By Investing.com
Investing.com· 2 weeks ago:SASY) (NASDAQ:SNY), marking a significant milestone for the vaccine developer. The deal, which...
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
FX Empire via Yahoo Finance· 1 week agoThe past five days have been a rollercoaster for Novavax investors, as the share price of the...
Explainer-What are the FLiRT COVID variants and are they more contagious?
KFGO· 3 hours agoBy Michael Erman NEW YORK (Reuters) - The so-called FLiRT variants of SARS-CoV-2 coronavirus that...
Could Novavax Become the Next Moderna?
Motley Fool via Yahoo Finance· 1 week agoNovavax's combined coronavirus/flu vaccine candidate as well as a stand-alone flu candidate performed well in clinical trials, and the company started...
Could current COVID vaccines protect against future outbreaks? New study offers hope
Orange County Register· 22 hours agoA group of researchers had the future in mind when they asked if current COVID-19 vaccines and...
Free COVID-19 vaccines could be a thing of the past as federal program is set to expire early
Chicago Sun-Times· 1 day agoBiden administration officials are seeking permanent funding so that routine vaccinations can remain...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with Strategic Partnerships and Cost ...
GuruFocus.com via Yahoo Finance· 2 weeks agoIn response, Novavax is implementing cost reduction strategies aimed at significantly decreasing R&D and SG&A expenses in 2025 to below $500 million. Furthermore, the company ...
